araag2/HINT huggingface dataset:
Clinical trial NCT00369707 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed low-grade B-lymphocyte non-Hodgkins lymphoma

          -  Life expectancy > 12 months

        Exclusion Criteria:

          -  No known history of HIV infection

          -  No other active infection

          -  No peripheral neuropathy ≥ grade 2 within the past 14 days

          -  No uncontrolled hypertension

          -  None of the following cardiac conditions:

               -  Myocardial infarction within the past 6 months

               -  No heart failure

               -  Uncontrolled angina

               -  Severe uncontrolled ventricular arrhythmias

               -  Electrocardiographic evidence of acute ischemia

               -  Active conduction system abnormalities

          -  No serious medical or psychiatric illness that would preclude study compliance

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior therapy for non-Hodgkins lymphoma

          -  No prior bortezomib or rituximab

          -  At least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic
             anticancer biologic therapy, or anticancer hormonal therapy

          -  At least 2 weeks since prior investigational drugs

          -  No other concurrent systemic cytotoxic chemotherapy or investigational agents + No
             leukemia
Clinical trial NCT00383188 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, ph-797804, ph-797804, ph-797804, ph-797804
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with RA and has failed at least 1 DMARD therapy

        Exclusion Criteria:

          -  Any other inflammatory arthritis and any significant history of acute or chronic
             infection with immunomodulatory etiology
Clinical trial NCT00638716 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: cjc-1134-pc, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Major Inclusion Criteria:

          -  BMI: 27 to 45 kg/m2

          -  Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator

          -  Stable life-style, i.e. diet & physical activity, as determined by the Investigator

          -  Stable metformin daily dose ≥1000 mg for at least 3 months

          -  Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%
Clinical trial NCT01641809 (phase 2, status: completed)
Conditions: infection, human immunodeficiency virus, hiv infections
ICD codes: Z21, Z21
Drugs: gsk1265744 10 mg, gsk1265744 30 mg, gsk1265744 60 mg, efavirenz 600 mg, rilpivirine 25 mg, placebo, abacavir/lamivudine (abc/3tc) or tenofovir/emtricitabine (tdf/ftc)
SMILES: C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N12, FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1, CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infected male or female subjects >= 18 years of age

          -  Screening plasma HIV-1 RNA >=1000 c/mL

          -  CD4+ cell count >=200 cells/millimeter (mm)^3

          -  ART-naive defined as having =<10 days of prior therapy with any antiretroviral agent
             following a diagnosis of HIV-1 infection

          -  Female subjects of child bearing potential are eligible to enter if they are not
             pregnant and willing to use protocol-specified methods of contraception to prevent
             pregnancy during the study

        Exclusion Criteria:

          -  Any evidence at screening of an active Centers for Disease and Prevention Control
             (CDC) Category C disease

          -  Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

          -  History of ongoing or clinically relevant hepatitis within the previous 6 months, and
             subjects with moderate to severe hepatic impairment will be excluded

          -  Women who are breastfeeding

          -  Subject, who in the investigator's judgment, poses a significant suicide risk

          -  Any clinically significant finding on screening or baseline electrocardiograph (ECG)

          -  The presence of any specific laboratory abnormalities at Screening

          -  History of cardiac disease

          -  Clinically relevant pancreatitis

          -  Subjects who are unlikely to complete the dosing schedule due to a pre-existing
             physical or mental condition

          -  Any condition which impairs the absorption, distribution, metabolism or excretion of
             the investigational product

          -  Any evidence of primary resistance based upon the presence of a major resistance
             associated mutation in the Screening HIV genotype, or any historical genotype

          -  Treatment with any protocol-specified excluded medication
Clinical trial NCT01053962 (phase 2, status: completed)
Conditions: chronic idiopathic constipation
ICD codes: K59.04
Drugs: sp-304 0.3 mg, sp-304 1.0 mg, sp-304 3.0 mg, sp-304 9.0 mg, placebo
SMILES: CC1CCC2=C(C1)C1=C(OC2(C)C)C=C(C)C=C1OC(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is able to understand and willing to sign the Informed Consent Form (ICF) and
             capable of providing written authorization for use and disclosure of protected health
             information per requirements of 45 CFR 164.508 (Health Insurance Portability and
             Accountability Act [HIPAA]).

          -  Subject is male or non-pregnant, non-breastfeeding female, between 18 and 75 years of
             age (inclusive) at the time of first dose.

          -  Subject has a body mass index (BMI) between 18 and 35 kg/m2.

          -  Subject meets the Rome III Diagnostic Criteria for constipation (Drossman, 2006) for
             the past 3 months with symptom onset > 6 months prior to diagnosis.

        Exclusion Criteria:

          -  Subject reports loose stool (fluffy pieces with ragged edges, a mushy stool) or watery
             stool (no solid pieces, entirely liquid; BSFS score of 6 or 7, respectively) in the
             absence of any laxative, enema, suppository or prohibited medicine for > 25% of BMs
             during the 3 months prior to the Screening visit and during the 14 day pre-treatment
             period.

          -  Subjects who meet the Rome III criteria for IBS.

          -  Subject has failed to complete the pre-treatment bowel movement diary accurately and
             completely during the pre-treatment period prior to Day 1 dosing.
Clinical trial NCT01318070 (phase 2/phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin and pioglitazone, alogliptin and pioglitazone, pioglitazone
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16
             weeks prior to the start of the treatment period (Week 0).

          2. Had glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 14 weeks after
             the start of the observation period (Week -2).

          3. Had HbA1c difference within 10.0%* at 10 weeks after the start of the observation
             period (Week -6) and 14 weeks after the start of the observation period (Week -2) from
             10 weeks after the start of the observation period (Week -6) (*rounded off to the
             first decimal place).

          4. Was receiving specific diet and exercise (if any) therapies during the observation
             period.

        Exclusion Criteria:

          1. Had taken a diabetic medications other than pioglitazone within 16 weeks before the
             start of the treatment period (Week 0).

          2. Had a history or symptoms of cardiac failure.
Clinical trial NCT00652340 (phase 2, status: completed)
Conditions: recurrent non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: apricoxib/erlotinib, erlotinib/placebo
SMILES: CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically determined Stage IV NSCLC including Stage IIIb (pleural effusion)

          -  Failed at least one prior platinum-based chemotherapy for Stage IIIb or Stage IV
             NSCLC. Patients receiving platinum-based chemotherapy only given in an adjuvant
             setting are not eligible.

          -  Measurable disease by RECIST

          -  Greater than or equal to 18 years of age

          -  ECOG PS of 0 or 1

        Exclusion Criteria:

          -  Radiation therapy within 2 weeks; chemotherapy within 3 weeks; non-cytotoxic
             investigational agents within 4 weeks of initiating study treatment

          -  Evidence of NYHA class III or greater cardiac disease

          -  History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality
             within 12 months

          -  Known HIV infection or AIDS

          -  Symptomatic CNS metastases

          -  Pregnant or nursing women

          -  Hypersensitivity or intolerance to erlotinib, sulfonamides, aspirin, or other NSAIDs.

          -  History of upper GI bleeding, ulceration, or perforation

          -  Prior history of COX-2 inhibitor therapy for the treatment of metastatic NSCLC

          -  Previous anti-EGFR kinase therapy
Clinical trial NCT00550173 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, erlotinib
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer

          -  Patients must be non-smokers

          -  Patients must have at least one measurable lesion

          -  Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale

          -  Patients must have failed only one prior chemotherapy regimen and must be considered
             eligible for further chemotherapy following progression of their disease.

        Exclusion Criteria:

          -  Patients who have received treatment within the last 30 days with a drug that has not
             received regulatory approval for any indication

          -  Patients who have previously received treatment with drugs against the human epidermal
             growth factor receptors

          -  Patients who have previously received treatment with drugs which have similar targets
             as Pemetrexed

          -  Patients who have any known significant ophthalmologic abnormalities of the surface of
             the eye

          -  Patients who have a history of severe hypersensitivity reaction to erlotinib or
             pemetrexed
Clinical trial NCT00402168 (phase 2, status: completed)
Conditions: renal transplant
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: belatacept, cyclosporine a, tacrolimus
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Men and women age 18 and older

          -  6-36 months after kidney transplant receiving cyclosporine or tacrolimus

          -  calculated GFR ≥35 and ≤75mL/min/1.73 m²

          -  subjects must have completed 1 year in the IM103-010ST and remained on study treatment
             (Long Term Extension)

        Key Exclusion Criteria:

          -  Significant infection

          -  acute rejection within 3 months

          -  prior graft loss due to rejection

          -  pregnancy

          -  positive crossmatch
Clinical trial NCT00413114 (phase 2, status: completed)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: obatoclax mesylate (gx15-070ms)
SMILES: COC1=CC(=N\C1=C/C1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathological confirmation of Myelodysplastic Syndromes (MDS)

          -  Patients must have had no prior systemic therapy

          -  Must have normal organ functions

          -  Must have the ability to understand and willingness to sign a written informed consent
             form

        Exclusion Criteria:

          -  Must not be a result of prior chemotherapy and/or radiotherapy for another malignancy

          -  No other agents or therapies administered in the intent to treat

          -  Uncontrolled, intercurrent illness

          -  Pregnant women and women who are breast feeding
Clinical trial NCT01128452 (phase 2, status: terminated)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: evt 101, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    evotec has indicated that this study was discontinued due to a clinical hold issued by the fda
  
Eligibility criteria:

        Inclusion Criteria:

          -  Major Depressive Disorder

          -  Current episode of major depression that has not benefited from at least 1 but no more
             than 3 adequate treatment regimens

          -  Has as score of >/= 18 on the Ham-D-17

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Evidence of age-related cognitive decline or mild dementia

          -  At imminent risk of committing suicide

          -  Has with the exception of major depression, a serious medical or neurological illness,
             including seizure disorder, stroke, dementia, or Parkinson disease

          -  Has an established diagnosis of bipolar disorder, hypomania, schizoaffective disorder,
             major depression with psychotic features or schizophrenia

          -  Has had a substance or alcohol abuse or dependence disorder (except nicotine and
             caffeine) in the 1 year before screening
Clinical trial NCT01265524 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: clp, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Heart failure with New York Heart Association (NYHA) Classification III or IV

          -  Hospitalization for heart failure decompensation associated with fluid overload within
             the last six months

          -  Chronic kidney disease

          -  Must be able to understand study procedures and willing and able to provide written
             informed consent

        Exclusion Criteria:

          -  No hospitalization within 4 weeks of Baseline Visit

          -  In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine,
             gastrointestinal, neurological or other disease or condition that makes the patients
             study participation unsafe

          -  History or presence of gastrointestinal conditions such as severe constipation or
             gastrointestinal tract strictures

          -  Current dialysis patient, or anticipated need for dialysis during study participation
Clinical trial NCT01059864 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550, atorvastatin, cp-690,550, atorvastatin placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  must be diagnosed as having active rheumatoid arthritis

          -  agree to participate in the study and sign and informed consent document

        Exclusion Criteria:

          -  History of serious infection within the past 6 months

          -  test positive for TB

          -  have any uncontrolled clinically significant disease or laboratory tests

          -  require administration of prohibited medications during the study
Clinical trial NCT01426009 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: ep-101 via nebulizer (eflow®) 25 ug, ep-101 via nebulizer (eflow®) 50 ug, ep-101 via nebulizer (eflow®) 100 ug, placebo ep-101, tiotropium bromide via (spiriva® handihaler®), ipratropium bromide inhalation solution via handihaler® dpi, ep-101 via nebulizer (eflow®) 200 ug
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  40-75 years of age

          -  Clinical diagnosis of moderate to severe COPD

          -  Current/ex-smokers with at least 10 pack-year smoking history

          -  Post-bronchodilator FEV1 ≥ 30% and ≤ 70% predicted normal values

          -  Post-bronchodilator FEV1/FVC ratio of ≤ 0.70

          -  Post-bronchodilator improvement in FEV1 ≥ 12% and ≤ 30%, and a minimum of 100 mL

          -  Willing and able to remain at the study site for at least 24 hours at each study visit

          -  Signed written informed consent

        Exclusion Criteria:

          -  Current evidence or recent history of any clinically significant and unstable disease
             or abnormality (e.g., myocardial infarction, cardiac failure, uncontrolled
             hypertension, life-threatening arrhythmias, uncontrolled diabetes)

          -  Primary diagnosis of asthma

          -  History of malignancy within the past 5 years

          -  History of COPD exacerbation within 6 weeks of Screening

          -  Daily oxygen therapy > 10 hours per day

          -  Systemic steroids use within 6 weeks of Screening

          -  Respiratory tract infection within 6 weeks of Screening

          -  History of tuberculosis, bronchiectasis

          -  History of urinary retention or bladder neck obstruction type symptoms

          -  History of glaucoma

          -  Prolonged QTc interval (>460msec) or history of long QT syndrome

          -  Recent history of alcohol or drug abuse

          -  Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling
             to practice acceptable birth control methods

          -  History of hypersensitivity or intolerance to aerosol medications

          -  Participation in another investigational drug study within 30 days of Screening
Clinical trial NCT01647451 (phase 2, status: completed)
Conditions: inflammation, rheumatoid arthritis
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: nnc0114-0006, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of RA meeting the 2010 ACR (American College of Rheumatology)
             classification criteria, obtained at least 6 months prior to dosing with the trial
             product. (If the diagnosis was made prior to 2010, a diagnosis meeting the 1987 ACR
             classification criteria is acceptable)

          -  Active RA characterised by DAS28-CRP (disease activity score based on 28 joints and
             c-reactive protein) equal to or above 4.5 and at least five tender and five swollen
             joints (can be the same joints) of the 28 joint count

          -  Concomitant treatment with MTX above or equal to 15 mg/week for at least 4 months
             prior to screening, with stable dose of between or equal to 15 mg/week and 25 mg/week
             for at least 6 weeks prior to screening (MTX doses between 7.5 and 12.5 mg/week are
             allowed, if patient had intolerance to 15 mg/week)

          -  Biologic naïve subjects or subjects having been treated with biologics for RA
             (biologic experienced) provided they meet one of the following criteria: a. Reason for
             discontinuation of biologic therapy was intolerance (e.g., unable to receive
             recommended doses or achieve adequate treatment duration because of drug related side
             effects), b. Discontinued biologic therapy for other reasons than lack of efficacy
             (primary or secondary failure) or intolerance (e.g., drug holiday)

        Exclusion Criteria:

          -  Body mass index (BMI) below or equal to 18.0 or above or equal to 38.0 kg/m^2

          -  Subjects with rheumatic autoimmune disease other than RA, or significant systemic
             involvement secondary to RA (including but not limited to vasculitis, pulmonary
             fibrosis, or Felty's syndrome). Subjects with secondary Sjögren's syndrome or stable
             hypothyroidism are eligible

          -  Any active or ongoing bacterial infections within 4 weeks prior to randomisation,
             unless treated and resolved with appropriate therapy (e.g., simple urinary tract
             infection)

          -  Any history of recurrent infections or conditions predisposing to chronic infections
             (e.g., bronchiectasis, chronic osteomyelitis)

          -  History of severe systemic fungal infection within the past 12 months prior to
             screening unless treated and resolved with appropriate therapy